Toregem BioPharma Passes AMED Stage Gate Evaluation under the “Strengthening Program for Pharmaceutical Startup Ecosystem”
Toregem BioPharma Co., Ltd. is pleased to announce that our project, “Development of a new antibody drug to treat congenital tooth agenesis,”has successfully passed the interim Stage Gate evaluation under the “Strengthening Program for Pharmaceutical Startup Ecosystem (Open Call for Drug Discovery Ventures)”administered by the Japan Agency for Medical Research and Development (AMED) in 2025. […]
Honoka Kiso CEO, Honoka Kiso CEO received " Glorious Women Award" at "Kansai Business Seminar Award" held on Feb.2026
This prize was awarded to the female leaders who challenges and takes actions contributing to the development of business in Kansai.Also, regarding this prize, our efforts have been introduced in Newspapers, The Nikkei and Kyoto shimbun. The articles featured our progress of research and development of tooth regenerative drugs and the challenges for the Social […]
Honoka Kiso, CEO, spoke at an event hosted by Nakanoshima Qross Drug Discovery and Commercialisation
Spoke at a seminar entitled "A Thorough Analysis of the Pitfalls of Drug Discovery Startups: Practical Knowledge to Overcome. Them with Limited Resources (Drug Discovery Cluster Campus Project)" under the theme of "Social implementation of regenerative medical care and the role of startups".Shared specific examples of the progress of research and development of tooth regenerative […]
Notification of receipt of response regarding Pre -IND meeting with the US FDA
Tregem Biopharmaceuticals Inc. (Kyoto City, President and CEO: Honoka Kiso; hereinafter referred to as "Tregem") has been holding pre-IND meetings with the U.S. Food and Drug Administration (FDA) for the U.S. development of an antibody drug (development code: TRG-035) for congenital tooth agenesis.We are pleased to announce that we have now received an official response […]
Toregem’s Anti-USAG-1 Antibody “TRG035” Designated as an Orphan Drug by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Severe Congenital Oligodontia
Toregem BioPharma Co., Ltd. (Head Office: Kyoto City; CEO: Honoka Kiso; hereinafter referred to as Toregem)’s investigational anti-USAG-1 antibody 'TRG035” has been designated by the Ministry of Health, Labour and Welfare as an orphan drug for the target disease “severe congenital hypodontia”.20250929_TRG035_Severe_Congenital_Partial_Anodontia_Orphan_Drug_Japan.pdf